

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

Data Insights: Covid-2019 Monitor

Thursday, June 24, 2021

The global scorecard



For more information contact us:

Donald Luskin: 312 273 6766 don@trendmacro.com Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Copyright 2021 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.

The US scorecard

The ten worst US states															
New cas	New Deaths		New in hospital		Qume cases		Quime deaths		Qume in hospital		Hospital use	ICU use			
R.	+1,442	R.	+53	KY	+ 89	CA	3,811,723	CA	63,424	TX	252,386	RI 92%	MO 14%		
TX	+1,216	CA	+51	GA	+48	TX	2,989,604	NY	53,639	CA	239,030	MA 85%	WY 14%		
CA	+915	WA	+46	AR	+ 15	Æ	2,355,467	TX	52,183	R.	184,986	MO 82%	UT 11%		
MO	+841	TX	+33	L	+11	NY	2,112,649	R.	37,586	NY	136,011	PA 82%	00 11%		
WA	+803	CK	+30	MO	+7	IL T	1,389,892	PA	27,612	GA	108,528	CA 81%	ID 10%		
UT	+527	GA	+21	NV	+7	PA	1,215,374	NJ	26,410	PA	91,346	MD 81%	AR 10%		
ω •7	+504	NJ	+18	AZ	+6	GA	1,131,972	L	25,606	0H	87,353	CI 81%	WA 9%		
AZ	+490	AL	+1/	CA	+6	CH	1,109,697	GA	21,350	L	82,191	MN 79%	UK 8%		
	+482		+ 14		+0		1,021,822		20,914	ΚΥ -4ΝΙ/Λ	0	IVII 78%	IX 8%		
NC	+401	NC.	+11	UI	+0	NC	1,011,001	ч	20,213	#I¥A	1 250 295	L 70%	INV 0%		
	+7,001		7234		+201		10, 149,701		340,937		1,209,200				
All states	+13,878		+428		+17	All states	33 577 651		602 837		2 372 046	All states 70%	67%		
Tonten	55%		69%		1182%	Tonten	54%		58%		53%	Median 73%	5%		
TOP TOT	0070		0070		110270	iop ton	0470		Sc	ome states r	not reporting		070		
Five most improved US states															
Fewer da	Fewer daily cases Fewer new deaths Fewer new hospitalizations Most pop immunuity of											unuity growth			
TX	-758				ан	-47			TX .	-88		MP	+40 bp		
CA	-183				PA	-28			FL.	-22		FR	+30 bp		
WV	-183				MI	-12			IN	-16		SC	+30 bp		
AR	-96				MS	-12			AL	-14		ω	+20 bp		
MT	-54				MO	-11			ΤN	-14		MD	+20 bp		
350.000 -													- 10%		
330,000													12 /0		
300,000 -	Unit	ted Stat	es			As of Jun 23					- 10%				
	1030	877 bn of n	onulation i	nfected		2 week							- 10%		
	18 50	8 bn of non	ulation fat	alities							2-week fata	ality rate 2.07%			
250,000 -	38.1 r	nedian pop	ulation and	antioo						Cui	me fatality rate	1.80% –	00/		
aths	00.11	nouldin pop	alation age	,					MIII	Ν			- 8%		
ළ p 200.000 -								1		22.57	7 051		Cas		
as an								. A.		33,57	.2,436 cases t	oday			
case			1	1	1944 1944			M					- 0% ality		
<u>≩</u> 150,000 -					A.				'	60	2,837 deaths o	cumulative	rate		
laily					N.			N'I		l l	+375 deaths	today			
100.000						.		<u> </u>		۳\			- 4%		
100,000 -			7-day mo	iving average ca	ses	· · · · · · · · · · · · · · · · · · ·		M		V					
			1		A	4A .		Kanana ang K			AA. A	NAA. \\`			
50,000 -		- N				Maria	MA ANY.	1.11	······		MAN	·····	.* 2%		
			r MM	An		VVV	MAAA .								
			ď	-man	/V							' MM	N		
	1 En	h 10	Apr 0	May O) I.I.I.1	8 Con	6 Oct	26	Dec 15	Enh 3	Marí)5 May 14			
Dec 3	1 Fe	b 19	Apr 9	May 29	A/* 	.8 Sep	6 Oct	26	 Dec 15	Feb 3	Mar 2	25 May 14	0%		

Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

Noming out the vaccines in the US and the World												
US overall	US overall Total						To	day	Immunity	Full	Partial	
Doses distributed		392,472,915						+0.564 million		US	45.1%	53.2%
Doses administered		329,321,907						+0.658	million	UK	46.8%	64.0%
Administered		One dose		% Pop Im		nune	% рор	New immune today		France	25.5%	47.7%
Total population		18	182,548,513		1	54,876,177	46%	+0.368 million		Spain	32.4%	50.8%
Age 12 to 17		8,336,571		33%		5,867,668	23%	+0.069 million		Germany	33.2%	51.9%
Age 18 to 64		124,646,253		61%	1	05,130,077	52%	+0.254 million		ltaly	27.5%	53.4%
Age 65 and	lover	49,405,154		90%	90% 43,777,198		80%	+0.043	million	Australia	4.3%	22.6%
J	&J									Israel	59.6%	63.7%
L	1%					At today's	s dosing p	ace,		Canada	21.9%	67.1%
				every American >18 immune in						Japan	8.7%	19.6%
Moderna		St	ato			200		Africa	1.0%	2.5%		
41%	55%	00	416	by Feb 6, 2022						India	3.7%	17.5%
	00%	Immunities	distributed							Brazil	11.6%	31.5%
		as % pop	ulation**			71.2% of	population	nized	Global data diffe	rs from sources,	timing	
AK		At least part	tial immunity	14.1% previously te				ted positive	;	China NA	ME	
60.7%	as % po	pulation	Best 85.3% vs 60% adult herc					munity*		72.3%		
48.0% Full immunity			imunity	N.C.						65.9%		
41.9% as % populat				Middle							60.3%	
						WI					NH	
				Worst 54.9%						77.4%	71.0%	
				53.1%						73.3%	61.7%	
						48.1%				64.5%	54.9%	
	WA	ID	MT	ND	MN	IL	MI		NY	MA		
	64.5%	49.2%	54.8%	49.0%	60.6%	60.8%	61.0%		64.2%	73.3%		
	60.3%	39.2%	47.2%	43.5%	56.4%	58.5%	51.0%		59.2%	69.7%		
	53.1%	35.4%	41.7%	38.3%	50.4%	44.6%	46.2%		52.5%	60.2%		
	OR	NV	WY	SD	IA	IN	OH	PA	NJ	СТ	RI	
	70.2%	52.2%	47.3%	57.3%	57.4%	52.4%	55.5%	64.7%	67.8%	69.2%	73.8%	
	57.9%	48.4%	38.8%	50.1%	51.0%	44.0%	47.8%	62.1%	64.3%	66.2%	63.9%	
	51.8%	40.8%	33.8%	44.8%	47.2%	39.2%	43.8%	48.7%	55.1%	59.2%	57.5%	
	CA	UT	CO	NE	M0	KY	WV	VA	MD	DE		
	65.0%	52.7%	63.5%	56.4%	52.0%	52.4%	55.5%	63.2%	72.9%	68.5%		
	60.3%	47.9%	57.2%	50.5%	44.2%	48.9%	42.9%	58.4%	60.7%	57.4%		
	48.5%	36.5%	50.5%	45.8%	38.2%	42.4%	36.6%	50.6%	54.2%	48.2%		
		AZ	NM	KS	AR	TN	NC	SC	DC			
		58.1%	59.4%	55.5%	49.7%	48.6%	58.4%	54.1%	78.7%			
		48.9%	60.9%	48.6%	41.3%	41.1%	44.8%	43.5%	60.4%			
		39.3%	52.6%	41.1%	33.5%	34.6%	38.8%	37.4%	50.9%			
				OK	LA	MS	AL	GA		_		
				53.3%	45.8%	47.2%	51.5%	55.0%				
				44.2%	37.6%	35.7%	39.2%	42.5%				
				37.4%	33.9%	29.2%	32.0%	35.4%		-		
HI				TX							PR	
71.2%				57.7%	6						68.0%	
69.2%				47.5%	52						56.0%	
51.1%				40.0%		As of Jun 23		44.3%		43.5%		

Rolling out the vaccines in the LIS and the world

* Includes persons >18 fully immunized or previosuly tested positive, no overlap. Disregards untested positives, natural immunities.

** One dose of Pfizer/Moderna counts as half an immunity, one dose of J&J as a full immunity

Source: CDC, CDC, Our World in Data, TrendMacro calculations



Source: Johns Hopkins, Covid Act Now, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

Recommended reading

Chinese Covid-19 Gene Data That Could Have Aided Pandemic Research Removed From NIH Database Amy Dockser Marcus, Betsy McKay and Drew Hinshaw *Wall Street Journal* June 23, 2021

Recovery of deleted deep sequencing data sheds more light on the early Wuhan SARS-CoV-2 epidemic Jesse D Bloom *medRvx* June 22, 2021 Nanopore Targeted Sequencing for the Accurate and Comprehensive Detection of SARS-CoV-2 and Other Respiratory Viruses Ming Wang et al.

Nano Micro Small June 24, 2020

Meme of the day



Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP







The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality, log scale*

Source: Johns Hopkins, TrendMacro calculations



Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Johns Hopkins, TrendMacro calculations

Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Covid Act Now, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations





Patient zero... and then everyone else

Source: Johns Hopkins, TrendMacro calculations







Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations

Impact in other hot-spots



Impact in the BRICs ex-China



19



Impact in the Middle East and Africa

